OS2966

News alerts, weekly reports and conference planners

Company:

Renovaro Biosci

Drug class:

β1 integrin inhibitor

‹

›

3years

Trial Update -Results of a phase I window of opportunity trial evaluating a first-in-class CD29 inhibitor, OS2966, in recurrent high-grade glioma (SNO 2022)

Initial data demonstrate the safety and feasibility of direct intracranial delivery of OS2966.

3 years ago

P1 data

ITGB1 (Integrin Subunit Beta 1)

VEGFA expression

OS2966

4years

Initial results of a phase I window of opportunity trial evaluating a first-in-class CD29 inhibitor, OS2966, in recurrent high-grade glioma (SNO 2021)

Pharmacodynamic analysis via tissue-level biomarkers is ongoing and will be presented. CONCLUSION Initial data demonstrates the safety and feasibility of direct intracranial delivery of OS2966.

4 years ago

P1 data

ITGB1 (Integrin Subunit Beta 1)

OS2966

over4years

Role of c-Met/β1 integrin complex in the metastatic cascadein breast cancer. (PubMed, JCI Insight)

OS2966, a therapeutic antibody disrupting c-Met/β1 binding, decreased breast cancer cell invasion and mesenchymal gene expression...Thus, the c-Met/β1 complex drives intravasation of triple-negative breast cancer cells and preferential affinity for bone-specific matrix. Pharmacological targeting of the complex may prevent metastases, particularly osseous metastases.

over 4 years ago

Journal

MET (MET proto-oncogene, receptor tyrosine kinase)

MET mutation

OS2966